Abcellera Biologics Inc (ABCL)

$10.89 +0.43 (4.11%)
Market Cap 3.21B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 4,378,300
Avg Vol 7,196,424
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 38%
Beta 1.32
Analysts Strong Sell
Price Target $17.12

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
snowPOW
snowPOW Sep. 13 at 7:39 AM
$ABCL $BB my two favourite tickers trends #1 and #2 Ha
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 7:33 AM
$ABCL GET in NOW!! Get in Monday PRE-Market!! $14’ssss-15’sss Coming this WEEK!! READ MY POSTS! CARL’s CANTOR CONFERENCE CALL was the Best 30 Minute Call I have EVER LISTENED too‼️ CARL MENTIONED that Patients were “CURED” going from 10 EVENTS a day to “ZERO”‼️ 😮 🤯 People are WAKING UP!! NO MORE $10’sss!! Too VALUABLE of a Company. $ABCL is a GAME-CHANGER! 🚨🚨🚨 HUGE BUYS Came on FRIDAY’s Closing!! OVER 2,500,000 MILLION! 👇🏻👇🏻 1 REASON and 1 REASON ONLY‼️ SOMETHING LEAKED‼️ A DEAl was 🖋️ inked and ✍️ on Friday whatever deal was signed probably was completed around 2.00pm FRIDAY. *** PARTNERSHIP?? *** MORE Money?? *** Phase 2 -12 week Data?? People HAVE LISTENED to the CALL on Friday and OVER the WEEKEND ‼️ These $10’ss are GONE! ABCL WILL CONTINUE its UPWARD MOVEMENT to $14’sss-$15’ssss!! PR will HIT 7.30am Monday or AFTER HOURS‼️
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 6:46 AM
$ABCL ADDED 10K MORE‼️ $ABCL OVER $2,500,000 Million JUST BOUGHT in the last 1 hour. 🤯 People are WAKING UP‼️ Forget Monday we Close ABOVE $11’sss TODAY!!! 🚨‼️READ my POST’s!! You Will UNDERSTAND WHY!! GET IN NOW!!! ABCL too VALUABLE NO MORE $10’s! Investors are digesting all the Nuggets Carl spoke about on the conference! It’s a MUST LISTEN! 🎧 🎧 👂 Best 30 minute Conference call I have EVER LISTENED TOO!!! ‼️Don’t be FOOLED! Market Conditions has ABCL trading at a huge discount this week! Wait until many people listen 👂 to the call today and this weekend we will be OPENING in the Mid 11’ssss on MONDAY!!! AS people spend Today listening to CALL and the WEEKEND digesting this information. 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From ten events a day to “ZERO” 🤯 🤯 GET in NOW!!!! $13-$15’sss next week for SURE‼️ 💯 $ABCL 🔥 🚀 $10–11 consolidation → reclaim $11.31 → break $12.2 → $13.24 → $15–16 → potentially $18.29.
1 · Reply
XxZeeMoneyxX
XxZeeMoneyxX Sep. 13 at 5:58 AM
$ABCL looking forward to next week!! We ride at dawn.
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 5:46 AM
$ABCL ABCL635 may become a much bigger drug than we think. The $6B TAM is just for menopause. When you factor in moderate to severe VMS caused by undergoing treatment for breast and prostate cancer, you have another opportunity to help a lot of people. The TAM may be smaller but comparable. If they clear safety in phase 2 and phase 3, I think we will be on a rocket ride for the next 10 years. Good luck!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 1:02 AM
$ABCL $ABCL Follow the signal | RE: ABCL635 “We think we have a product that if we can translate this through to phase IlI, and there is no reason to think that we cannot, that it could be the dominant product for non-hormonal treatment of menopause symptoms.” $6B TAM in the U.S. and this is only the first of many internal molecules to come from AbCellera. We are in chapter 1.
0 · Reply
Rastafari
Rastafari Sep. 12 at 2:46 PM
$ABCL Check out two key positions that have just opened up at AbCellera: 1. (Senior) Director, Drug Safety & Pharmacovigilance Operations 2. Regulatory Submissions Specialist Coincidence? Maybe. But these are exactly the types of roles you’d expect to see being added as a drug moves closer to the regulatory process. Carl Hansen is building out the team needed to advance ABCL635 toward regulatory submission—and ultimately, approval. And here’s the interesting part: if the RIGHT partner emerges with the RIGHT commercial terms, a partnership or deal could happen much sooner—potentially well before 2030. The pieces are starting to line up. Keep connecting the dots!
2 · Reply
MagicRon_
MagicRon_ Sep. 12 at 6:29 AM
$ABCL "Better luck next week" LOL do you realise you lost 5% MC this week 🤣👎🐻
1 · Reply
SCSyndrome
SCSyndrome Sep. 12 at 2:44 AM
$ABCL
0 · Reply
et1000
et1000 Sep. 11 at 11:15 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $ABCL $FBIO $SNDX $TGTX :A
0 · Reply
Latest News on ABCL
AbCellera Biologics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 2:10 PM EDT - 3 days ago

AbCellera Biologics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

Sep 2, 2026, 4:05 PM EDT - 10 days ago

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera rises 17.0%

2026-08-25T16:06:05.000Z - 18 days ago

AbCellera rises 17.0%

AbCellera rises 10.7%

2026-08-25T14:06:36.000Z - 19 days ago

AbCellera rises 10.7%

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

Aug 13, 2026, 12:05 AM EDT - 4 weeks ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 4 weeks ago

AbCellera announces $200M common stock, warrants offering

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 11, 2026, 4:01 PM EDT - 4 weeks ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 4 weeks ago

AbCellera price target raised to $30 from $12 at Truist

AbCellera price target raised to $25 from $13 at JonesResearch

2026-08-10T19:55:32.000Z - 4 weeks ago

AbCellera price target raised to $25 from $13 at JonesResearch

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 4 weeks ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 4 weeks ago

AbCellera Biologics Transcript: Study result

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 4 weeks ago

AbCellera Biologics Press release: Study result

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 4 weeks ago

AbCellera Biologics Slides: Study result

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:23 AM EDT - 4 weeks ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

Aug 10, 2026, 7:13 AM EDT - 4 weeks ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

2026-08-10T11:11:27.000Z - 4 weeks ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Aug 7, 2026, 4:30 PM EDT - 5 weeks ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 5 weeks ago

AbCellera price target raised to $9 from $8 at Stifel

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

2026-08-06T12:12:02.000Z - 5 weeks ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Slides: Q2 2026

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings release: Q2 2026

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Quarterly report: Q2 2026

AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera Reports Q2 2026 Business Results

AbCellera announces collaboration with Vertex Pharmaceuticals

2026-07-29T11:27:06.000Z - 6 weeks ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

Jul 29, 2026, 7:00 AM EDT - 6 weeks ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

2026-07-09T21:29:02.000Z - 2 months ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Jul 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 2 months ago

AbCellera apponts Lynn Seely to board of directors

LYEL

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 3 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 4 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 7 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 8 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 8 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 8 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

snowPOW
snowPOW Sep. 13 at 7:39 AM
$ABCL $BB my two favourite tickers trends #1 and #2 Ha
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 7:33 AM
$ABCL GET in NOW!! Get in Monday PRE-Market!! $14’ssss-15’sss Coming this WEEK!! READ MY POSTS! CARL’s CANTOR CONFERENCE CALL was the Best 30 Minute Call I have EVER LISTENED too‼️ CARL MENTIONED that Patients were “CURED” going from 10 EVENTS a day to “ZERO”‼️ 😮 🤯 People are WAKING UP!! NO MORE $10’sss!! Too VALUABLE of a Company. $ABCL is a GAME-CHANGER! 🚨🚨🚨 HUGE BUYS Came on FRIDAY’s Closing!! OVER 2,500,000 MILLION! 👇🏻👇🏻 1 REASON and 1 REASON ONLY‼️ SOMETHING LEAKED‼️ A DEAl was 🖋️ inked and ✍️ on Friday whatever deal was signed probably was completed around 2.00pm FRIDAY. *** PARTNERSHIP?? *** MORE Money?? *** Phase 2 -12 week Data?? People HAVE LISTENED to the CALL on Friday and OVER the WEEKEND ‼️ These $10’ss are GONE! ABCL WILL CONTINUE its UPWARD MOVEMENT to $14’sss-$15’ssss!! PR will HIT 7.30am Monday or AFTER HOURS‼️
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 6:46 AM
$ABCL ADDED 10K MORE‼️ $ABCL OVER $2,500,000 Million JUST BOUGHT in the last 1 hour. 🤯 People are WAKING UP‼️ Forget Monday we Close ABOVE $11’sss TODAY!!! 🚨‼️READ my POST’s!! You Will UNDERSTAND WHY!! GET IN NOW!!! ABCL too VALUABLE NO MORE $10’s! Investors are digesting all the Nuggets Carl spoke about on the conference! It’s a MUST LISTEN! 🎧 🎧 👂 Best 30 minute Conference call I have EVER LISTENED TOO!!! ‼️Don’t be FOOLED! Market Conditions has ABCL trading at a huge discount this week! Wait until many people listen 👂 to the call today and this weekend we will be OPENING in the Mid 11’ssss on MONDAY!!! AS people spend Today listening to CALL and the WEEKEND digesting this information. 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From ten events a day to “ZERO” 🤯 🤯 GET in NOW!!!! $13-$15’sss next week for SURE‼️ 💯 $ABCL 🔥 🚀 $10–11 consolidation → reclaim $11.31 → break $12.2 → $13.24 → $15–16 → potentially $18.29.
1 · Reply
XxZeeMoneyxX
XxZeeMoneyxX Sep. 13 at 5:58 AM
$ABCL looking forward to next week!! We ride at dawn.
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 5:46 AM
$ABCL ABCL635 may become a much bigger drug than we think. The $6B TAM is just for menopause. When you factor in moderate to severe VMS caused by undergoing treatment for breast and prostate cancer, you have another opportunity to help a lot of people. The TAM may be smaller but comparable. If they clear safety in phase 2 and phase 3, I think we will be on a rocket ride for the next 10 years. Good luck!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 13 at 1:02 AM
$ABCL $ABCL Follow the signal | RE: ABCL635 “We think we have a product that if we can translate this through to phase IlI, and there is no reason to think that we cannot, that it could be the dominant product for non-hormonal treatment of menopause symptoms.” $6B TAM in the U.S. and this is only the first of many internal molecules to come from AbCellera. We are in chapter 1.
0 · Reply
Rastafari
Rastafari Sep. 12 at 2:46 PM
$ABCL Check out two key positions that have just opened up at AbCellera: 1. (Senior) Director, Drug Safety & Pharmacovigilance Operations 2. Regulatory Submissions Specialist Coincidence? Maybe. But these are exactly the types of roles you’d expect to see being added as a drug moves closer to the regulatory process. Carl Hansen is building out the team needed to advance ABCL635 toward regulatory submission—and ultimately, approval. And here’s the interesting part: if the RIGHT partner emerges with the RIGHT commercial terms, a partnership or deal could happen much sooner—potentially well before 2030. The pieces are starting to line up. Keep connecting the dots!
2 · Reply
MagicRon_
MagicRon_ Sep. 12 at 6:29 AM
$ABCL "Better luck next week" LOL do you realise you lost 5% MC this week 🤣👎🐻
1 · Reply
SCSyndrome
SCSyndrome Sep. 12 at 2:44 AM
$ABCL
0 · Reply
et1000
et1000 Sep. 11 at 11:15 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $ABCL $FBIO $SNDX $TGTX :A
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 8:19 PM
$ABCL Just ADDED 10K‼️ $ABCL OVER $2,500,000 Million JUST BOUGHT in the last 1 hour. 🤯 People are WAKING UP‼️ Forget Monday we Close ABOVE $11’sss TODAY!!! 🚨‼️READ my POST’s!! You Will UNDERSTAND WHY!! GET IN NOW!!! ABCL too VALUABLE NO MORE $10’s! Investors are digesting all the Nuggets Carl spoke about on the conference! It’s a MUST LISTEN! 🎧 🎧 👂 Best 30 minute Conference call I have EVER LISTENED TOO!!! ‼️Don’t be FOOLED! Market Conditions has ABCL trading at a huge discount this week! Wait until many people listen 👂 to the call today and this weekend we will be OPENING in the Mid 11’ssss on MONDAY!!! AS people spend Today listening to CALL and the WEEKEND digesting this information. 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From ten events a day to “ZERO” 🤯 🤯 GET in NOW!!!! $13-$15’sss next week for SURE‼️ 💯 $ABCL 🔥 🚀 $10–11 consolidation → reclaim $11.31 → break $12.2 → $13.24 → $15–16 → potentially $18.29.
0 · Reply
Odoji
Odoji Sep. 11 at 8:19 PM
$ABCL 💉
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 8:14 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 8:13 PM
$ABCL
0 · Reply
DeMampCamp
DeMampCamp Sep. 11 at 8:05 PM
$ABCL Damn Ron, this didn't age well, lmao! Better luck next week pal, I'd start drinking now if I were you
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 7:55 PM
$ABCL
0 · Reply
8008track
8008track Sep. 11 at 7:53 PM
$ABCL somebody knows something - they know what they own. Don’t trade for pennies when you could be holding Benjamins.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 7:52 PM
$ABCL $ABCL OVER $2,000,000 Million JUST BOUGHT in the last 1 hour. 🤯 People are WAKING UP‼️ Forget Monday we Close ABOVE $11’sss TODAY!!! 🚨‼️READ my POST’s!!! You Will UNDERSTAND WHY!! GET IN NOW!!! ABCL too VALUABLE NO MORE $10’s! Investors are digesting all the Nuggets Carl spoke about on the conference! It’s a MUST LISTEN! 🎧 🎧 👂 Best 30 minute Conference call I have EVER LISTENED TOO!!! ‼️Don’t be FOOLED! Market Conditions has ABCL trading at a huge discount this week! Wait until many people listen 👂 to the call today and this weekend we will be OPENING in the Mid 11’ssss on MONDAY!!! AS people spend Today listening to call and the weekend digesting this information. 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From ten events a day to “ZERO” 🤯 🤯 GET in NOW!!!! $13-$15’sss next week for SURE‼️ 💯 $ABCL 🔥 🚀 $10–11 consolidation → reclaim $11.31 → break $12.2 → $13.24 → $15–16 → potentially $18.29.
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 7:49 PM
$ABCL ABSOLUTELY 💯!!!
0 · Reply
Rastafari
Rastafari Sep. 11 at 7:45 PM
$ABCL whatever deal was signed probably was completed around 2.00pm today. PR will hit AH or 7.30am Monday!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 11 at 7:19 PM
$ABCL Investors are digesting all the Nuggets Carl spoke about on the conference! It’s a MUST LISTEN! 🎧 🎧 👂 Best 30 minute Conference call I have EVER LISTENED TOO!!! 🚨People are BUYING UP all the ABCL Shares they can today! ‼️Don’t be FOOLED! Market Conditions has ABCL trading at a huge discount this week! Wait until many people listen 👂 to the call today and this weekend we will be OPENING in the Mid 11’ssss on MONDAY!!! If you wait until next week you will be paying in the 11’sss and 12’sss. This is going to $13-15’sss next week for sure as people spend today listening to call and the weekend digesting this information. 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From ten events a day to “ZERO” 🤯 🤯 Read my Posts!!! GET in NOW!!!! $13-$15’sss next week!! $ABCL 🔥 🚀 ABCL is too valuable won’t be in the $10’s too long. $10–11 consolidation → reclaim $11.31 → break $12.2 → $13.24 → $15–16 → potentially $18.29.
2 · Reply
Vippizipi
Vippizipi Sep. 11 at 7:14 PM
$ABCL vote yes 👍
0 · Reply